Glioblastoma (GBM) is the most frequent and devastating primary tumor of the central nervous system with a median survival of 12 to 15 months after diagnosis. GBM is highly difficult to treat due to its delicate location, inter- and intra-tumoral heterogeneity, and high plasticity in response to treatment. In this study, we intracranially implanted primary GBM cells into mice which underwent conventional GBM treatments, including irradiation, temozolomide, and a combination. We obtained single cell suspensions through a combination of mechanical and enzymatic dissociation of brain tissue and investigated in detail the changes in GBM cells in response to conventional treatments in vivo using multi-color flow cytometry and cluster analysis. CD44 expression was elevated in all treatment groups, which was confirmed by subsequent immunohistochemistry. High CD44 expression was furthermore shown to correlate with poor prognosis of GBM and low-grade glioma (LGG) patients. Together, these results indicate a key role for CD44 in glioma pathogenesis.

胶质母细胞瘤（GBM）是中枢神经系统中最常见，最具破坏性的原发肿瘤，诊断后中位生存期为12至15个月。GBM的位置，肿瘤间和肿瘤内的异质性以及对治疗的可塑性高，因此很难治疗。在这项研究中，我们将颅内原发性GBM细胞颅内植入经过常规GBM处理（包括放射，替莫唑胺和联合治疗）的小鼠中。我们通过脑组织的机械解离和酶解离解的结合获得了单细胞悬液，并使用多色流式细胞仪和聚类分析详细研究了响应于常规治疗的GBM细胞的变化。在所有治疗组中CD44表达均升高，这通过随后的免疫组织化学证实。此外，CD44高表达还与GBM和低度神经胶质瘤（LGG）患者的预后不良相关。在一起，这些结果表明CD44在神经胶质瘤发病机制中的关键作用。